Core Viewpoint - Action Education (605098.SH), the leading company in the A-share management training industry, continues to implement a high dividend strategy, proposing a cash dividend of 10 yuan per 10 shares for the 2025 interim dividend [2][4]. Financial Performance - In 2024, Action Education achieved a revenue of 783 million yuan, representing a year-on-year growth of 16.54%, and a net profit of 269 million yuan, up 22.39% year-on-year [3][9]. - The company has cumulatively realized a net profit of 770 million yuan over four years [3]. Dividend History - Since its listing in April 2021, Action Education has implemented multiple dividend distributions, totaling 1.02 billion yuan, which is 1.76 times the total amount raised during its IPO [5][7]. - In 2024, the company increased its dividend frequency, distributing a total of 267 million yuan, which is comparable to its annual net profit of 269 million yuan [7][9]. Client Development - In 2024, Action Education developed over 1,200 new clients, including 295 new major clients, indicating significant growth in its customer base [3][9]. Business Segments - The main business segments of Action Education include management training, management consulting services, and related sales of books and audio-visual products [9][10]. - In 2024, the revenue from management training, management consulting, and book sales was 633 million yuan, 146 million yuan, and 3.05 million yuan, respectively, with growth rates of 6.31%, 97.38%, and 47.07% [10]. Asset and Financial Position - As of March 2025, Action Education's total assets amounted to 2.183 billion yuan, with a debt-to-asset ratio of 54.33% [8].

雅本化学此前表示，公司着眼全球战略布局，构建由六个核心生产基地与两个参股协作生产基地共同组 成的供应链格局。其中，太仓基地全力推进转型升级，从传统农、医药中间体生产，向战新产品领域拓 展；南通基地依托先进工艺与设备，从事创新农药高级中间体高端定制；盐城基地作为公司唯一具备农 药全产业链生产能力的基地，满足定制客户需求的同时凭借丰富产品线参与市场竞争；兰州基地推动数 字化建设，保障新订单高效落地，并以医药中试助力研发成果商业化；上虞基地具备生物酶产品快速规 模化的生产能力；马耳他基地借助独特区位优势，聚焦原料药及特色API定制生产，助力国内外资源整 合，拓展欧洲市场。 7月29日晚间，雅本化学（300261）发布公告称，公司拟终止筹划对外投资收购甘肃皓天科技股份有限 公司部分存量股份和/或认购新增注册资本的事项。此前，公司曾披露拟终止筹划对外投资的提示性公 告。 公司半年度业绩预告显示，今年上半年，公司归属于上市公司股东的净利润为亏损1000万元—500万 元，上年同期亏损5201.36万元。公司表示，报告期内，公司持续聚焦主业，深化客户合作，全力推动 年度经营计划落地实施。在此基础上，公司半年度业绩较上年同期 ...

Group 1: Company Overview and Strategy - The company is currently in the process of renewing its cooperation agreement with FMC, with ongoing discussions on relevant terms [1] - The company is implementing a "big customer strategy," transitioning to a diversified model with several core enterprise customers and multiple key innovative products [1][2] - The company has established long-term partnerships with leading pesticide companies, indicating a high entry barrier in the CDMO business [3] Group 2: Financial Performance and Challenges - The company reported a loss of 258 million yuan in 2024, primarily due to a goodwill impairment of 106 million yuan and a cyclical downturn in the pesticide industry [5] - The company’s short-term loans increased by 42.7%, with a debt ratio of 46.11%, but it maintains a strong repayment capability and has never defaulted [9] Group 3: Business Development and Future Plans - The company has a clear strategic plan for its pharmaceutical business, focusing on expanding GMP-compliant production capacity and maintaining a "big customer strategy" [7] - The Yancheng base is operational, with the second phase ready for use, expected to positively contribute to the pesticide business [8] - The company is cautiously expanding its health business, leveraging its synthetic biology and chemical synthesis technology platforms [10] Group 4: Research and Development - The company emphasizes a technology-driven development strategy, maintaining high R&D investment despite recent performance challenges [12] - The company aims to enhance its core competitiveness and build a solid technological barrier through continuous product development [12] Group 5: Shareholder Relations and Market Management - The company has not declared dividends for 2024 but maintains a positive attitude towards future dividend policies [13] - The company has implemented a market value management plan to enhance its business foundation and maintain investor relations [14]

Group 1: Company Performance and Financials - The company's pharmaceutical production line has a low capacity utilization rate due to the inclusion of historical cooperative production orders in the reported capacity, leading to a discrepancy between reported and actual utilization rates. However, the actual utilization is at a good level, with stable revenue and profit from the pharmaceutical sector [1] - In Q1 2025, the company experienced significant improvement in operations, with the agricultural protection sector stabilizing its gross margin and the pharmaceutical sector developing steadily. This was aided by an increase in foreign exchange gains and a turnaround from losses to profits in foreign exchange hedging derivatives, resulting in a notable increase in net profit [1] - The company anticipates a breakthrough in revenue from its new energy business in 2025, despite facing pressure from intense market competition and depreciation costs from fixed assets [1] Group 2: Business Development and Strategy - The pharmaceutical business is expected to grow in 2025, focusing on "key customers," primarily leading global pharmaceutical companies based in Europe. The company is enhancing existing partnerships while developing new clients and strengthening R&D capabilities [2] - The company is actively communicating with clients and developing projects in the new energy sector, with plans to introduce products like electrolytes and additives to the market [4] - The UK and Malaysia factories are part of a strategy to provide stable supply chains and comprehensive product delivery capabilities. The UK factory is expected to see improved capacity utilization and profitability in 2025, while the Malaysia factory is still in the construction phase [5][6] Group 3: R&D and Product Development - The development cycle for new agricultural protection products is generally shorter than that for pharmaceutical products, with the company providing kilogram-scale samples after clients complete molecular efficacy validation [3] - The company has invested significantly in R&D across agricultural protection, pharmaceuticals, and functional chemicals, achieving partial commercialization of products and production lines in 2024. Future R&D efforts will focus on optimizing existing products and extending advantageous technologies based on client needs [6]

Core Insights - Company achieved record revenue in Q1 2025, driven by a decade-long strategy of targeting major clients, continuous technological innovation, and responsiveness to global market changes [1][9][12] Group 1: Company Performance - In Q1 2025, the company reported revenue of 5.55 billion yuan and a net profit of 460 million yuan, marking a year-on-year growth of 12.47% [9][12] - For the full year 2024, the company achieved revenue of 24.03 billion yuan, a 20.12% increase, and a net profit of 1.94 billion yuan, up 174.19% [9][12] - The average selling price of products increased by approximately 9.43% in Q1 2025, with a gross margin of 26.81% [12] Group 2: Market Position and Industry Dynamics - The global polyurethane market is projected to grow from 81.4 billion USD in 2024 to 112 billion USD by 2029, indicating strong demand for high-performance materials [4] - The polyurethane industry in China has low market concentration, with the top four companies holding only 19.3% of the market share, leading to intense competition [8] - The company has positioned itself as a leader in the polyurethane composite materials sector, leveraging technological innovation to develop differentiated products [8][9] Group 3: Client Relationships and Strategic Partnerships - The company has successfully established partnerships with major global brands such as Nike, Adidas, and Apple, enhancing its market presence [16][18] - After a decade of effort, the company became a strategic partner of Nike, which significantly boosted its market access and credibility [16][18] - The company’s sales to the U.S. market represent only 2.55% of total revenue, indicating limited exposure to potential tariff impacts [20][22] Group 4: Technological Innovation - The company has focused on developing high-performance, multifunctional, and eco-friendly products, which has allowed it to maintain a competitive edge [8][9] - Recent advancements include the introduction of over 30 new materials, such as water-based and solvent-free products, which have increased their market appeal [9][12]

Group 1: Market Performance - The overseas market experienced a year-on-year growth of 19.88% in 2024, achieving a revenue of 518 million [1] - The company has 16 years of experience in overseas market expansion, covering over 100 countries and regions [1] - The demand for digital equipment in the denture processing industry is slowing down in China, the US, and Europe, while the chairside market still holds significant potential [2] Group 2: Product Development and Sales - The company completed the acquisition of Korean Wolan in May 2024, with expected revenue of over 18 million in the second half of 2024 [2] - The narrow-neck implant and digital surgical tool kit from Wolan are expected to receive NMPA certification this year, with the ALL-ON-X occlusion reconstruction plan set to launch soon [3] - Sales of zirconia products are maintaining a medium to high growth rate, with stable prices and improved gross margins [6] Group 3: International Strategy and Risk Management - The European market accounts for the highest share of overseas revenue, followed by the Americas, with notable growth in the Middle East and Asia [4] - The US tariff policy has a controllable impact on the company's exports, with 38.15% of revenue coming from the domestic market, providing growth space and policy support [4] - The company plans to increase inventory at its US subsidiary to mitigate short-term impacts from tariffs [5] Group 4: Client Strategy and Market Expansion - In 2024, the company achieved significant results in large client cooperation, increasing the procurement budget share from major clients [6] - The company aims to build a global ecosystem of large and quality clients, promoting industry progress [6] - The company is enhancing brand building for Wolan and providing diverse training courses to strengthen market promotion [3] Group 5: Future Growth and Value Creation - The company expects stable growth in overseas business due to product quality, technological innovation, and customer service advantages [8] - The company focuses on core business development and technological innovation to enhance market competitiveness and profitability [9] - A stable cash dividend policy and improved investor relations management are part of the company's value realization strategy [9]

Investment Rating - The report maintains a "Buy" rating for the company [2] Core Views - The company achieved a revenue of 695 million yuan in 2024, representing a year-on-year growth of 48.3%, and a net profit of 45 million yuan, up 10.3% year-on-year, which met expectations [7] - The company plans to distribute a cash dividend of 3.0 yuan per share (including tax) for 2024, with a distribution ratio of 56.71% [7] - In Q1 2025, the company reported a revenue of 162 million yuan, a year-on-year increase of 40.1%, and a net profit of 9 million yuan, up 8.8% year-on-year, slightly below expectations [7] - The company is focusing on a major client strategy and has formed partnerships with emerging brands to drive revenue growth, with domestic revenue reaching 642 million yuan in 2024, a 40.5% increase [7] - The company is enhancing its raw material research and investment to improve integrated capabilities and increase the value-added of its OEM services [7] - The profit forecast for 2025-2027 has been adjusted downwards, with expected net profits of 69 million yuan, 91 million yuan, and 115 million yuan respectively [7] Financial Data and Profit Forecast - Total revenue is projected to reach 1,009 million yuan in 2025, with a year-on-year growth rate of 45.2% [6] - The gross profit margin is expected to be 26.4% in 2025, with a net profit margin of 6.5% [6] - The company’s return on equity (ROE) is forecasted to be 15.6% in 2025 [6] - The earnings per share (EPS) is projected to be 0.81 yuan in 2025 [6]

4月23日，雅本化学（300261）股份有限公司(股票代码：300261)正式发布2024年年度报告。尽管受行 业周期波动及市场竞争加剧影响，公司业绩短期承压，但通过深化主业布局、强化研发投入及优化管理 结构，雅本化学在核心业务领域展现出较强的韧性，为未来高质量发展奠定了坚实基础。 报告期内，雅本化学实现营业收入12.02亿元，同比下降6.00%；归属于上市公司股东的净利润为-2.58亿 元，亏损同比扩大。这一表现主要受农药行业景气度下行、产品价格波动及市场竞争等因素影响。 然而，细分业务数据显示，公司核心主业仍保持稳定增长：农药中间体业务收入6.81亿元，同比增长 2.06%；医药中间体业务收入3.33亿元，同比增长1.10%。 公司坚持"大客户战略"，与跨国农化巨头及创新药企建立深度合作，形成了"核心客户+重点产品"的业 务矩阵。南通基地、兰州基地等生产基地的产能爬坡及新项目落地，进一步巩固了公司在定制生产 (CDMO)领域的市场地位。此外，盐城基地作为唯一具备农药全产业链生产能力的基地，有效提升了供 应链稳定性。 面对行业挑战，雅本化学逆势加大研发投入，技术壁垒持续筑高。2024年研发费用达1.23亿元 ...

Core Insights - The company reported a total revenue of 783 million yuan for 2024, representing a year-on-year growth of 16.54% and a net profit attributable to shareholders of 269 million yuan, up 22.39% year-on-year [1] - In Q4 2024, the company achieved revenue of 221 million yuan, a year-on-year increase of 4.47%, and a net profit of 74 million yuan, reflecting a growth of 25.84% year-on-year [1] - The revenue growth is attributed to the successful implementation of a major client strategy and continuous enhancement of brand strength [1] - The company emphasizes shareholder returns, proposing a cash dividend distribution of 267 million yuan (before tax), which accounts for 99.47% of the net profit attributable to shareholders [1] Business Segmentation - The management consulting business saw significant revenue growth, nearly doubling year-on-year [2] - Management training business generated revenue of 630 million yuan in 2024, a growth of 6.31%, with a gross margin of 83.63%, an increase of 1.47 percentage points from the previous year [2] - Management consulting business achieved revenue of 146 million yuan, a remarkable growth of 97.38%, although the gross margin decreased by 4.07 percentage points to 44.24% [2] - As of the end of 2024, the company's contract liabilities stood at 1.08 billion yuan, reflecting a year-on-year increase of 12.7% and a quarter-on-quarter growth of 11.9% [2] Future Plans and Projections - For 2025, the company plans to add 500 new major clients and leverage AI large model technology to develop intelligent education products in niche areas to enhance efficiency for enterprises [2] - The company aims to achieve a "double nine target" with a major client repurchase rate of over 90% and a referral rate of over 90% [2] - Profit forecasts indicate that the net profit attributable to shareholders is expected to reach 300 million yuan in 2025, 340 million yuan in 2026, and 370 million yuan in 2027, maintaining a "recommended" rating [2]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price based on the last closing price of 39.15 [1][8] Core Views - The company achieved a revenue of 783.43 million yuan in 2024, representing a year-on-year growth of 16.54%, and a net profit attributable to shareholders of 268.57 million yuan, up 22.39% from the previous year [4][9] - The overall gross margin for the year was 76.05%, a decrease of 2.21 percentage points, primarily due to the structural change from the increase in management consulting revenue [5] - The company has a strong focus on large clients, having developed over 1,200 new clients in the year, with 295 being new large clients, which supports continued revenue growth [6] Financial Performance - In Q4 2024, the company reported revenue of 221 million yuan, a year-on-year increase of 4.47%, and a net profit of 73.97 million yuan, up 25.84% [4][5] - The company’s contract liabilities reached a new high of 1.08 billion yuan, with new signed orders of 933 million yuan, reflecting a 3.78% increase from 2023 [7] - The company plans to distribute a cash dividend of 0.75 yuan per share, totaling 89.44 million yuan, which represents 99.47% of the annual net profit attributable to shareholders [7] Future Projections - The company is expected to achieve net profits of 313.14 million yuan, 359.64 million yuan, and 405.24 million yuan for 2025, 2026, and 2027 respectively, with growth rates of 16.59%, 14.85%, and 12.68% [9] - The projected earnings per share (EPS) for 2025, 2026, and 2027 are 2.63 yuan, 3.02 yuan, and 3.40 yuan respectively, with corresponding price-to-earnings (PE) ratios of 15X, 13X, and 11X [8][9]